Like tens of thousands of Massachusetts residents, community college professor Carolyn McGrath has been paying for medicine ...

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

Mass General Brigham researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications, such as semaglutide or tir ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ ...

Only three drugs – Novo Nordisk’s Wegovy and Saxenda, and Eli Lilly’s Zepbound – are actually ... of these drugs to patients seeking affordable alternatives. This trend is particularly ...

President Trump was talking to reporters Friday after Dr. Oz's swearing-in ceremony when the news conference abruptly ended.

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Affordability metrics show housing costs squeezing household finances, pressures made more intense by a long-term shortage of low-cost housing. Affordability in general was a top issue in the 2024 ...

Shares of weight-loss drugmakers Novo Nordisk A/S and Eli Lilly and Co. got a nice lift Monday, after a potential competitor decided to cancel development of its GLP-1 obesity drug. “We continue ...

Affordability metrics show housing costs squeezing household finances, pressures made more intense by a long-term shortage of lost-cost housing. Affordability in general was a top issue in the 2024 ...

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...